Roberts CW, Orkin SH. The SWI/SNF complex–chromatin and cancer. Nat Rev Cancer. 2004;4(2):133–42.

Article  CAS  PubMed  Google Scholar 

Wu RC, Wang TL, Shih IM. The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther. 2014;15(6):655–64.

Article  PubMed  PubMed Central  Google Scholar 

Mullen J, et al. Targeting ARID1A mutations in cancer. Cancer Treat Rev. 2021;100:102287.

Article  CAS  PubMed  Google Scholar 

Heinze K, et al. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8(+) TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. J Pathol. 2022;256(4):388–401.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cerami E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.

Article  PubMed  Google Scholar 

Gao J, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.

de Bruijn I, et al. Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal. Cancer Res. 2023;83(23):3861–7.

Article  PubMed  PubMed Central  Google Scholar 

Jones S, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330(6001):228–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liang H, et al. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res. 2012;22(11):2120–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim YB, et al. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer. Int J Cancer. 2019;145(4):916–26.

Article  CAS  PubMed  Google Scholar 

Sun D, et al. Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency. Cell Commun Signal. 2023;21(1):48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee SH, et al. ARID1A mutation from targeted next-generation sequencing predicts primary resistance to gemcitabine and cisplatin chemotherapy in advanced biliary tract cancer. Cancer Res Treat. 2023;55(4):1291–302.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Itamochi H, et al. Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary. Int J Clin Oncol. 2015;20(5):967–73.

Article  CAS  PubMed  Google Scholar 

Reddy D, Bhattacharya S, Workman JL. (mis)-Targeting of SWI/SNF complex(es) in cancer. Cancer Metastasis Rev. 2023;42(2):455–70.

Article  PubMed  PubMed Central  Google Scholar 

He S, et al. Structure of nucleosome-bound human BAF complex. Science. 2020;367(6480):875–81.

Article  CAS  PubMed  Google Scholar 

Mardinian K, et al. SMARCA4: implications of an altered chromatin-remodeling gene for cancer development and therapy. Mol Cancer Ther. 2021;20(12):2341–51.

Article  CAS  PubMed  Google Scholar 

Yu C, et al. ARID1A loss derepresses a group of human endogenous retrovirus-H loci to modulate BRD4-dependent transcription. Nat Commun. 2022;13(1):3501.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang L, et al. The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ. Nature. 2018;563(7730):265–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shen J, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mengoli V, et al. WRN helicase and mismatch repair complexes independently and synergistically disrupt cruciform DNA structures. EMBO J. 2023;42(3):e111998.

Article  CAS  PubMed  Google Scholar 

Guan B, Wang TL, Shih IM. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011;71(21):6718–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun X, et al. Arid1a has context-dependent oncogenic and tumor suppressor functions in liver cancer. Cancer Cell. 2017;32(5): p. 574–589.e6.

Suryo Rahmanto Y, et al. Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming. Nat Commun. 2020;11(1):2717.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mao TL, Shih IM. The roles of ARID1A in gynecologic cancer. J Gynecol Oncol. 2013;24(4):376–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, et al. Chromatin remodelling molecule ARID1A determines metastatic heterogeneity in triple-negative breast cancer by competitively binding to YAP. Cancers (Basel), 2023;15(9).

Megino-Luque C, et al. ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma. Mol Oncol. 2022;16(11):2235–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takahashi K, et al. Treatment strategies for ARID1A-deficient ovarian clear cell carcinoma. Cancers (Basel). 2021;13(8).

Katagiri A, et al. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol. 2012;25(2):282–8.

Article  CAS  PubMed  Google Scholar 

Luo Q, et al. ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2. Cancer Lett. 2018;427:9–17.

Article  CAS  PubMed  Google Scholar 

Wu S, et al. Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. Nat Cancer. 2021;2(2):189–200.

Article  CAS  PubMed  PubMed Central  Google Scholar 

World Health Organization. Endometriosis. 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/endometriosis. Cited 2023 July.

Gadducci A, et al. Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes. Gynecol Oncol. 2021;162(3):741–50.

Article  PubMed  Google Scholar 

Fonseca MAS, et al. Single-cell transcriptomic analysis of endometriosis. Nat Genet. 2023;55(2):255–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anglesio MS, et al. Cancer-Associated Mutations in Endometriosis without Cancer. N Engl J Med. 2017;376(19):1835–48.

Article  PubMed  PubMed Central  Google Scholar 

Faizan U, Muppidi V. Uterine cancer. Treasure Island, FL: StatPearls 2023.

Li L, et al. Genome-wide mutation analysis in precancerous lesions of endometrial carcinoma. J Pathol. 2021;253(1):119–28.

Article  CAS  PubMed  Google Scholar 

Asaka S, et al. ARID1A Regulates Progesterone Receptor Expression in Early Endometrial Endometrioid Carcinoma Pathogenesis. Mod Pathol. 2023;36(2):100045.

Article  PubMed  Google Scholar 

Matsuzaki S, et al. Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity. Gynecol Oncol. 2021;160(2):586–601.

Article  CAS  PubMed  Google Scholar 

Leskela S, et al. Molecular basis of tumor heterogeneity in endometrial carcinosarcoma. Cancers (Basel). 2019;11(7).

Moreira-Barros J, Huang KG, Tsai TH. Radiation-Induced Uterine Carcinosarcoma after Concurrent Chemoradiotherapy for Cervical Squamous Cell Carcinoma. Rev Bras Ginecol Obstet. 2018;40(12):800–2.

Article  PubMed  PubMed Central  Google Scholar 

Kahraman K, et al. Uterine carcinosarcoma associated with pelvic radiotherapy for sacral chordoma: a case report. Taiwan J Obstet Gynecol. 2012;51(1):89–92.

Article  PubMed  Google Scholar 

Ahmed TB, et al. Radiotherapy-induced uterine cacinosarcoma: A case report and review of the literature. Int J Surg Case Rep. 2022;94:106977.

Article  PubMed  PubMed Central  Google Scholar 

Matsu